drugset / Trial / NCT01766375
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was a multi-center, open, randomized-control study on the effects and safety of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program on the overall survival rate and disease-free survival rate of acute myeloid leukemia patient in high-risk group over a period of 2 years.
Timeline
- Start
- 2012-08
- Primary completion
- 2016-01
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclosporine | Peptide | 5 mg/kg | Intravenous |
| Background | Methotrexate | Small molecule | 10 mg/m2 | — |
| Background | Mycophenolate Mofetil | Small molecule | 0.25 g | — |
| Background | Mycophenolate Mofetil | Small molecule | 0.5 g | — |